Nasdaq

Chembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis System

MEDFORD, N.Y., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced receipt of a ...
Business Insider

Chembio Diagnostics Receives WHO Prequalification Approval for HIV Self-Test

MEDFORD, N.Y., Nov. 04, 2019 (GLOBE NEWSWIRE) -- November 4, 2019 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today ...
Nasdaq

Chembio Diagnostics Submits FDA De Novo/510(k) Request for DPP SARS-CoV-2 Antigen Test System

HAUPPAUGE, N.Y., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it has ...
Benzinga.com

BIOSYNEX SA: CHEMBIO DIAGNOSTICS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A DPP CONGENITAL SYPHILIS ASSAY

BIOSYNEX SA BIOSYNEX SA: CHEMBIO DIAGNOSTICS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A DPP CONGENITAL SYPHILIS ASSAY 23-Oct-2024 / 18:00 CET/CEST Dissemination of a French ...
Seeking Alpha

Chembio Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis System

HAUPPAUGE, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission to the U ...